Gillespie Named Interim Associate Senior VP of Development and Alumni Affairs
The office of development and alumni affairs raises more than $20 million annually for the UC colleges of medicine, nursing, pharmacy and allied health sciences. It also serves the more than 20,000 graduates of the four health professions colleges.
We look forward to working closely with John as we work to engage our alumni and friends throughout the community in support of
Gillespie has been associated with the university for the past 30 years. Since 1998 he has served as director of marketing and development for UC Physicians, the 500-member faculty group practice. He also serves as executive director and treasurer of the Medical Center Fund of Cincinnati, which invests the reserves for the UC Physicians practices.
Prior to those appointments he served in a variety of administrative leadership roles with clinical departments at the
A native of
Gillespie will continue to serve with UC Physicians and the Medical Center Fund of Cincinnati during this interim period.
Related Stories
Make Hoxworth Blood Center’s special holiday events part of your family celebrations this December
December 12, 2025
This December, Hoxworth Blood Center, University of Cincinnati, is inviting families across Greater Cincinnati to add something truly meaningful to their holiday traditions: giving the gift of life. With festive community events, beloved local partners and special thank-you gifts for donors, Hoxworth is making it easier, and more heartwarming than ever, to roll up your sleeves and help save lives close to home.
Ohio nurses weigh in on proposed federal loan rule
December 12, 2025
Spectrum News journalist Javari Burnett spoke with UC Dean Alicia Ribar and UC nursing students Megan Romero and Nevaeh Haskins about proposed new federal student loan rules. Romero and Haskins, both seniors, were filmed in the College of Nursing’s Simulation Lab.
New combination treatment improves multiple myeloma outcomes
December 11, 2025
The University of Cincinnati Cancer Center's Ed Faber, DO, provided commentary to Medscape on the COBRA study that found the combination of carfilzomib combined with lenalidomide and dexamethasone (KRd) shows significantly greater efficacy than the previous standard of care.